Enteroviruses usually cause self-limited disease that, although associated with high morbidity, is rarely fatal. In certain patient populations, however, the enteroviruses may cause potentially life-threatening infections. Pleconaril is a novel compound that integrates into the capsid of picornaviruses, including enteroviruses and rhinoviruses, preventing the virus from attaching to cellular receptors and uncoating to release RNA into the cell. Pleconaril was used on a compassionate-release basis to treat patients with potentially life-threatening enterovirus infections, and for 38 of these patients sufficient follow-up data were available for determining responses to therapy. The enteroviruses include nearly 70 serotypes of closely related pathogens that cause a wide spectrum of human illness, from mild nonspecific fever to common upperrespiratory infections, aseptic meningitis, severe myocarditis, encephalitis, and paralytic poliomyelitis [1]. Subgroups of enteroviruses include the polioviruses, Coxsackieviruses A and B, echoviruses, and the newer numbered enteroviruses. An estimated 10-30 million enterovirus infections occur annually in the United States [2], causing significant short-term morbidity and economic impact [3] [4] [5] .
The enteroviruses include nearly 70 serotypes of closely related pathogens that cause a wide spectrum of human illness, from mild nonspecific fever to common upperrespiratory infections, aseptic meningitis, severe myocarditis, encephalitis, and paralytic poliomyelitis [1] . Subgroups of enteroviruses include the polioviruses, Coxsackieviruses A and B, echoviruses, and the newer numbered enteroviruses. An estimated 10-30 million enterovirus infections occur annually in the United States [2] , causing significant short-term morbidity and economic impact [3] [4] [5] .
Certain patients develop potentially life-threatening enterovirus infections for which therapeutic options have been limited. Antibody-deficient individuals infected with the enteroviruses may develop chronic men-ingitis or meningoencephalitis lasting many years, often with a fatal outcome [6, 7] . Recently, bone marrow transplantation (BMT) patients have been found to be both acutely [8] and chronically [9] infected with enteroviruses, resulting in potentially complicated and severe outcomes. The neonate, also relatively immunodeficient, appears to be at greatest risk for severe morbidity and mortality when signs and symptoms develop in the first days of life, suggesting transplacental acquisition with a high virus load [10] [11] [12] . The enteroviruses are also among the most commonly identified etiologies of myocarditis [13] . A minority of patients with enterovirus myocarditis go on to develop congestive heart failure, chronic myocarditis, or dilated cardiomyopathy [13] .
The enteroviruses are the most common cause of meningitis in the United States [14] and an important cause of encephalitis [15] . The latter neurological syndrome may result in substantial short-and long-term morbidity [15] . Recently, amyotrophic lateral sclerosis has again been linked to chronic enterovirus infection, reigniting a controversy of many years' standing [16] .
The atomic structure of the polioviruses, as resolved by computerized crystallographic studies, includes an icosahedral architecture with 60 identical "sides," each with a deep central cleft or canyon into which the specific cellular receptor for the enterovirus fits when the virus encounters a susceptible host cell [17] . Beneath the canyon lies a hydrophobic pocket into which a variety of diverse hydrophobic compounds can penetrate [17] . Pleconaril (3-{3,5-dimethyl-4-[[3-methyl-5-isoxazolyl}propyl]phenyl]-5-[trifluoromethyl]-1,2,4-oxadiazole; ViroPharma) integrates into that hydrophobic pocket and prevents viral replication by inhibiting viral uncoating and blocking viral attachment to host cell receptors [18, 19] . We report the preliminary outcomes of potentially lifethreatening enterovirus infections treated with pleconaril by compassionate-use protocol over a 2.5-year period beginning in autumn 1996.
PATIENTS AND METHODS
In autumn 1996, ViroPharma, the developer of pleconaril, made that drug available for compassionate administration to patients with potentially life-threatening enterovirus infections. Eligible patients included those with chronic enterovirus meningoencephalitis and agammaglobulinemia or hypogammaglobulinemia (CEMA), neonatal enterovirus sepsis, myocarditis, vaccine-associated or wild-type poliovirus infection, postpolio muscular atrophy syndrome, or enterovirus encephalitis, and BMT patients infected with enterovirus. Patients were referred to the study by physicians around the world who contacted one of the authors (H. A. R. or A. D. W.) or the drug manufacturer.
After the first 2.5 years of the compassionate-use program, there were 38 patients with sufficient follow-up information available for preliminary assessment of response to therapy. Responses were categorized as "clinical," "virological," "laboratory," and "radiological" and were based on comparison between specific parameters measured before and after pleconaril therapy. A clinical response was defined as diminishment of у1 of the prominent presenting symptoms or signs. For the purposes of this analysis, "no change" in a patient's condition was considered to be a nonresponse, although stabilization without disease progression may in fact represent a therapeutic response in some of these patients. Virological response was defined as reversion from enterovirus culture-positive to enterovirus culture-negative and/or from enterovirus PCR-positive to enterovirus PCR-negative. The methodologies for virological identification of enteroviruses by culture and reverse transcriptase PCR are detailed elsewhere [20] . A laboratory response included normalization or substantial improvement in a previously abnormal laboratory characteristic for the specific disease being treated (e.g., liver function, pleocytosis). Finally, several patients underwent either MRI or technetium-99 m-bisicate brain scanning or chest radiography before and after therapy; objective improvements in the findings of those studies were considered to be radiological evidence of response.
Children were treated for 7-10 days with 5.0 mg/kg per dose, 3 times per day. Adults received either 200 mg or 400 mg per dose, 3 times per day, for 7-10 days; the higher dose was chosen for most patients after the first few patients were observed to tolerate the lower dose without difficulty. Five patients received a second course of therapy because of their response to the initial course and either subsequent deterioration after therapy or a desire to further enhance the initial response. All treatment was by oral administration of a pleconaril suspension.
Adverse events were characterized according to their relationship to the study drug ("not related," "possibly related," "probably related," or "definitely related"), intensity ("mild," "moderate," or "severe"), outcome ("recovered," "improved," or "unchanged"), and seriousness ("serious" or "not serious").
RESULTS
The overall response rates are summarized in table 1, and individual patients are described in table 2. Among 17 evaluable patients with CEMA (table 2), the age range was 2-50 years (median, 16 years). The CEMA category heading, for purposes of this discussion, included patients with all types of Ig deficiencies. A total of 9 of these patients had congenital Bruton's type X-linked agammaglobulinemia, 4 had common variable immune deficiency, 2 had hyper IgM syndrome, 1 had deficiencies of IgA and subclasses IgG2 and IgG4, and 1 had severe combined immunodeficiency disease (SCID). An additional 2 patients (1 with Bruton's X-linked agammaglobulinemia and 1 with SCID) developed vaccine-associated poliovirus infection and were considered separately (see below). A total of 12 of the 16 CEMA patients for whom clinical responses were evaluable were judged to have had a clinical response to therapy: 9 with improved neurological status, 3 with growth/weight gain, 2 with diminished myositis/fasciitis, 1 with improved vision, and 1 with reduced hepatomegaly. An additional 4 patients remained stable (with neither improvement nor deterioration in their conditions) following therapy.
The data for 7 CEMA patients were sufficient for evaluation of virological responses. Six of the 7 were deemed to have had a virological response: 2 reverted from a culture-and PCRpositive status to culture-and PCR-negative status following therapy; 2 evaluated only by PCR reverted from positive to negative; 1 evaluated only by culture reverted from positive to negative following therapy; and 1 who remained culture-positive following therapy had a decreased virus level in quantitative measurement. Two patients (including one noted above with a reduced quantity of enterovirus and one with a negative virological response) had evidence of mixed infection with 2 enteroviruses. One patient was confirmed to be enterovirus culture-positive before therapy, but no follow-up cultures were performed; an additional 9 patients never had enterovirus infection confirmed but presented with typical CEMA features.
Nine CEMA patients had sufficient laboratory parameters measured to enable assessment of laboratory response; 8 patients appeared to have such a response. Most responses were with diminishment of pleocytosis or reduction in CSF protein levels following pleconaril therapy. One patient died of unrelated causes (accidental drowning), and the patient's brain was normal at autopsy, without evidence of infection. Of the 3 patients for whom both pre-and post-pleconaril therapy CNS imaging studies were done, improvement in their conditions was demonstrated for all (by technetium-99 m-bisicate scanning for 3 and by MRI for 1).
Six neonates with overwhelming enterovirus infection were treated with pleconaril. Two of the infants, who were twins (patients 57 and 58), were treated on day 7 of life (day 4 of illness). Both recovered completely. Two other infants, also twins (patients 71 and 72; table 2), were treated on days 4 and 5 of illness, respectively; they recovered with only mild sequelae. The other 2 infants, unrelated, were not treated until day 9 of illness. One of those patients (patient 16) survived with residual mild-to-moderate developmental delay; the other patient (patient XX; this patient was not assigned a number) died at age 28 days of persistent cardiac failure and adult-type respiratory distress syndrome. The 5 surviving babies all had evidence of laboratory response, and the 4 patients (including the fatal case) for whom pre-and postpleconaril therapy virological studies were performed reverted from testing enterovirus culture-positive before therapy to culture-negative after therapy.
Four patients with myocarditis, ranging in age from 3 months to 42 years, were treated with pleconaril; 3 of 4 had confirmed enterovirus infection. Three of the 4 patients had improved cardiac function after therapy (including 1 patient for whom enterovirus infection could not be confirmed). Two patients had pre-and postpleconaril therapy virological studies performed; one (patient 56) tested both culture-and PCR-negative after initially testing positive for enteroviruses by both methods, whereas the second (patient 66) tested negative for PCR after initially testing positive.
Four patients with BMT-related picornavirus infections (3 due to enterovirus, 1 due to rhinovirus) were treated with pleconaril. Patient 42, a 15-year-old with SCID due to underlying MHC class II deficiency who was in remission from a previous episode of echovirus 16 encephalitis, was given pleconaril prophylactically before, during, and after the transplantation procedure to prevent enterovirus-related complications; none developed. Because pleconaril was administered prophylactically in this case, this patient was not included in the response analysis. Two other patients (patients 41 and 59) developed symptomatic, virologically confirmed enterovirus infection following BMT. Both had clinical responses (neurological improvement and resolution of diarrhea in one and resolution of pleural and pericardial effusions and rash in the other). Another patient (patient 75), a 15-month-old leukemic child, developed severe rhinovirus pneumonia after undergoing transplantation and was treated with pleconaril; the child had a marked improvement in respiratory status during therapy but still required oxygen and had radiographic chest abnormalities. This patient is included in the analysis because of the close relatedness of rhinoviruses to the enteroviruses (both are genera within the Picornaviridae family) and the known susceptibility of rhinoviruses to pleconaril (see Discussion).
Three patients had acute poliovirus infections, 2 of which were vaccine-associated (in immunocompromised patients) and one of which was wild-type (patient 65, from the Middle East). Two of these patients had clinical responses (neurological improvement in 2 patients and improved respiratory status and muscle strength in 1 patient). The one patient who had preand postpleconaril therapy virological studies performed tested negative for poliovirus by both CSF culture and CSF-PCR after initially testing positive by both methods.
Finally, several patients with miscellaneous diseases proven or suspected to be due to enteroviruses were treated with pleconaril. A 76-year-old man (patient 34) with what was initially believed to be postpolio muscular atrophy syndrome had improved pulmonary function test values after undergoing therapy. Enterovirus infection in this individual could not be confirmed, and his diagnosis was subsequently confirmed to be amyotrophic lateral sclerosis. We include his analysis in the results because of the recently reported association between amyotrophic lateral sclerosis and enterovirus infection [16] . An 18-year-old previously healthy patient (patient 67) with acute onset of PCR-confirmed enterovirus transverse myelitis and encephalitis had both neurological and respiratory improvement temporally related to pleconaril therapy. Two patients with culture-confirmed enterovirus encephalitis were treated with pleconaril; one (patient 68) improved clinically and the condition of the other (patient 73) remained unchanged during and after therapy.
Adverse-events data were available for 32 of the 38 patients. Thirteen of the 32 patients experienced no adverse events. The remaining 19 patients had 56 adverse events: 1 patient had 5 adverse events, 2 patients had 6 each, and 1 patient had 9. Hence, among the 19 patients accounting for 56 adverse events, 4 patients had 26 of the reported events.
There were 8 deaths among these 32 patients. Patient 5 died of accidental drowning 1 year after therapy. Patient 7 died of cryptosporidial diarrhea 7 months after pleconaril treatment. Patient 12 died of chronic lung disease 1 week following therapy; this patient had X-linked agammaglobulinemia diagnosed 18 years before therapy and has been previously reported [21] . Patient 17 died of presumed sepsis due to her underlying disease (SCID) 4 months following therapy. Patient 24 died of aspergillosis 2 months following therapy. Patient XX died of progressive heart failure and adult-type respiratory distress syndrome 2 weeks following therapy with pleconaril. Patient 34 died of his underlying disease (amyotrophic lateral sclerosis) 1 year after treatment. Patient 59 died on day 6 of pleconaril therapy of pulmonary hemorrhage complicating acute myelogenous leukemia. Patient 66 died of carditis and disseminated intravascular coagulation 21 days after treatment. The physicians of the 8 patients who died did not believe that the deaths were related to pleconaril therapy.
Of the remaining adverse events, 7 were classified as "severe," 23 as "moderate," and 11 as "mild" in intensity. Eight of the nondeath adverse events were considered serious, and the rest were considered not serious. The relationships of the nondeath adverse events to treatment were determined by the patients' physicians to be the following: not related ( ), possibly n p 15 related ( ), probably related ( ), and definitely ren p 23 n p 7 lated ( ). The "probably related" adverse events were headn p 3 ache, stomachache, fatigue, anorexia, weakness, urinary incontinence, and worsening ataxia. The "definitely related" events included nausea (2 patients) and vomiting. A complete listing of adverse events is available by request.
DISCUSSION
Enteroviruses are among the most common causes of acute viral illness, with a broad spectrum of clinical manifestations [1] . Certain patients are uniquely susceptible to severe, potentially life-threatening enterovirus infections. In fall 1996 a specific antipicornavirus agent, pleconaril, became available for compassionate use in this group of at-risk patients. The preliminary results presented in this current report suggest that pleconaril has beneficial effects on clinical, virological, laboratory, and radiological parameters.
Children or adults with absent or deficient humoral immunity illustrate an important "experiment of nature" with regard to enterovirus infections of the CNS. Unlike other viruses, which are largely contained by innate and cognate cellular immunity, enteroviruses appear to be cleared from the host by predominantly antibody-mediated mechanisms. With the availability of iv preparations of Ig and the early recognition of enterovirus infection, fewer patients with humoral immunodeficiency appear to be progressing to the classic description of CEMA [6] , and atypical neurological presentations have appeared [7] . However, the fact that 17 CEMA patients were recruited into the Pleconaril Treatment Registry in the 2.5-year period of this study demonstrates that enterovirus disease remains an important complication in these patients.
Approximately 50% of these infected patients develop a rheumatologic syndrome, most often with features similar to dermatomyositis, which is also felt to be a direct result of enterovirus infection of the affected tissues [6] . Treatment with antibody preparations intravenously and intrathecally or intraventricularly has resulted in stabilization of the conditions of some of these patients; however, viral persistence has been documented during therapy [7] , and very few of these patients have survived their infections or the complications. Among the 16 patients with the CEMA syndrome treated with pleconaril for whom follow-up clinical data were available, 12 (75%) demonstrated a response temporally related to therapy. None of the 4 patients without clinical response were confirmed to be infected with enterovirus; they constituted nearly half of the 9 patients with the CEMA syndrome for whom confirmation of enterovirus infection was not possible. It is possible that some or all of these patients were infected with pathogens other than enteroviruses. A total of 7 patients with the CEMA syndrome whose enterovirus infections were confirmed demonstrated a clinical response, as did 5 of the patients for whom enterovirus infection could not be confirmed. Similarly high percentages of patients for whom virological and laboratory data were available for follow-up appeared to have responses in those categories. Although the natural history of this disease, untreated or treated only with Ig, can include periods of apparent improvement in clinical, virological, and laboratory parameters, the response rates observed among our patients are probably in excess of what would be expected without pleconaril. Furthermore, some patients in this study suffered neurological symptoms for many months or years, followed by improvement temporally related to treatment with pleconaril. Four CEMA patients died during the follow-up period of causes unrelated to enterovirus infection, reflecting the severity of these immunodeficiency disorders.
Young infants (aged р6 months) infected with enteroviruses usually develop nonspecific febrile illnesses, often accompanied by aseptic meningitis [5, 22] . These children generally recover uneventfully. However, when babies develop enterovirus infection within the first week of life, more severe disease is frequently seen. It is presumed that these babies acquire the infection perinatally and probably receive a higher viral inoculum, perhaps by means of transplacental bloodborne transmission [10] [11] [12] . Major systemic manifestations such as hepatic necrosis, myocarditis, encephalitis, pneumonia, necrotizing enterocolitis, and disseminated intravascular coagulation may develop, mimicking overwhelming bacterial infection [10] [11] [12] . When death occurs, it is typically due to hepatic failure or myocarditis. Among the 6 patients with overwhelming neonatal enterovirus infection in this pleconaril trial, 5 survived, including all 4 who were treated within the first week of illness. Sequelae among the surviving babies were mostly mild. The number of treated patients in this compassionate-use study is too small to determine whether the outcome was significantly improved in comparison with that for neonates not treated with pleconaril.
The enteroviruses have long been known to be important causes of acute myocarditis. The true incidence of that disease is unknown, as is the true incidence of an enterovirus etiology. Most cases of myocarditis are probably undiagnosed (presenting nonspecifically as viral illness without cardiac studies or, at the other extreme, as sudden death without autopsy) or, if diagnosed, have no identifiable cause. Enteroviruses may cause from 25% to 35% of cases of myocarditis for which a cause is found on the basis of serological study, nucleic-acid hybridization, and PCR-based studies of endomyocardial biopsy and autopsy specimens [13] . Neonates and young infants are particularly susceptible to coxsackie B virus-associated myocarditis accompanying systemic infection with those serotypes (see above). Most cases, however, involve young adults aged 20-39 years.
There were 4 patients with myocarditis in the present study, 3 of whom had clinical responses with improved cardiac function temporally related to pleconaril therapy. The variable natural history of this disease makes it impossible to draw definite conclusions regarding efficacy of pleconaril in cases of enterovirus myocarditis until further patients can be studied. Indeed, patient 56 had noticeably improved after receiving 1 or 2 doses of pleconaril, which may or may not be a biologically plausible expectation of therapy. Moreover, confounding the treatment of this disease is the role of postinfectious autoimmune damage to the heart so that active viral infection may no longer be the principal pathogenetic mechanism at the time of diagnosis [13] .
In conclusion, this preliminary study strongly suggests that pleconaril has both clinical and virological efficacy in patients with potentially life-threatening enterovirus infections. The long-recognized poor prognosis associated with enterovirus infection in patients with CEMA or overwhelming neonatal infection is in stark contrast to the 75% clinical response rate seen in pleconaril-treated patients with CEMA and the survival of all 4 neonates who were treated with pleconaril within the first week of illness. Similarly promising results, although also with small numbers of patients, were observed in cases of myocarditis, acute poliomyelitis, enterovirus infections complicating BMT, and other miscellaneous types of enterovirus infections. Pleconaril appeared to be safe and generally well-tolerated.
Pleconaril has been studied in trials involving numerous more commonly occurring picornavirus infections of healthy hosts, including large trials of the drug in cases of enterovirus meningitis in adults [23] and children [24] and in cases of viral respiratory infection (primarily with rhinoviruses) in adults [25] . In these studies, pleconaril has also been found to have clinical and virological benefit and a favorable safety profile.
Because of the relative rarity of enterovirus infections of the type described in this paper, it will be difficult to design placebocontrolled trials of pleconaril in these patient populations. Recent large outbreaks of severe enterovirus 70 and enterovirus 71 infections [26] provide additional motivation for studying pleconaril in cases of potentially life-threatening enterovirus infection. The Collaborative Antiviral Study Group of the National Institutes of Health has recently undertaken a placebocontrolled trial of pleconaril for treatment of neonatal enterovirus sepsis (Dr. David Kimberlin, personal communication). The availability of pleconaril for compassionate administration to patients with potentially life-threatening infections should encourage the clinicians caring for such patients to be aware of the possible enterovirus etiology of these diseases and to consider pleconaril therapy early in the course of the illness.
